RE:RE:OptionsI am quite sure they read the Stockhouse posts on Replicel to get a reading on what the retail shareholders are saying.
The more this update is delayed the more I think it has less to do with the Dermal Injector and more about taking the company private or selling it outright.
If this is the case it is all about the share price for either option. I know we all would like to see a big return on our investment and we all have different buy-in averages. Some would like to see $1.00+ to see a return on their investment while others can walk away with a profit at $.15.
Realistically there was at least 35,000,000 share placed at $.10 so there are many shareholders with averages less than $.25. Knowing that I think with either option the offer will be in the $.25/share range or less.
I know that will make many of the retail shareholders unhappy but they are a small group in the big picture and will be out voted.